1. Home
  2. GCDT vs GNPX Comparison

GCDT vs GNPX Comparison

Compare GCDT & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GCDT

Green Circle Decarbonize Technology Limited Ordinary Shares

N/A

Current Price

$0.78

Market Cap

9.9M

Sector

Industrials

ML Signal

N/A

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$0.84

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCDT
GNPX
Founded
1992
2009
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.9M
11.8M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
GCDT
GNPX
Price
$0.78
$0.84
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
32.9K
723.0K
Earning Date
05-16-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$0.14
52 Week High
$5.32
$12.97

Technical Indicators

Market Signals
Indicator
GCDT
GNPX
Relative Strength Index (RSI) 34.81 28.01
Support Level $0.72 $0.15
Resistance Level $1.50 $2.12
Average True Range (ATR) 0.09 0.06
MACD 0.03 0.02
Stochastic Oscillator 25.85 10.91

Price Performance

Historical Comparison
GCDT
GNPX

About GCDT Green Circle Decarbonize Technology Limited Ordinary Shares

Green Circle Decarbonize Technology Ltd is a company which provides advanced energy saving solutions supported by proprietary phase change thermal energy storage materials and thermal engineering services. As an advocate of decarbonization, the Company designs, develops and provides customized energy saving solutions that bring considerable economic benefits to our clients and reduce carbon emissions for a sustainable future.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Share on Social Networks: